Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
PLoS One. 2013;8(1):e54001. doi: 10.1371/journal.pone.0054001. Epub 2013 Jan 16.
Histone deacetylase (HDAC) inhibitors are promising anti-fibrosis drugs; however, nonselective inhibition of class I and class II HDACs does not allow a detailed elucidation of the individual HDAC functions in renal fibrosis. In this study, we investigated the effect of MS-275, a selective class I HDAC inhibitor, on the development of renal fibrosis in a murine model of unilateral ureteral obstruction (UUO) and activation of cultured renal interstitial fibroblasts.
METHODS/FINDINGS: The UUO model was established by ligation of the left ureter and the contralateral kidney was used as a control. At seven days after UUO injury, kidney developed fibrosis as indicated by deposition of collagen fibrils and increased expression of collagen I, fibronectin and alpha-smooth muscle actin (alpha-SMA). Administration of MS-275 inhibited all these fibrotic responses and suppressed UUO-induced production of transforming growth factor-beta1 (TGF-beta), increased expression of TGF-beta receptor I, and phosphorylation of Smad-3. MS-275 was also effective in suppressing phosphorylation and expression of epidermal growth factor receptor (EGFR) and its downstream signaling molecule, signal transducer and activator of transcription-3. Moreover, class I HDAC inhibition reduced the number of renal tubular cells arrested in the G2/M phase of the cell cycle, a cellular event associated with TGF-beta1overproduction. In cultured renal interstitial fibroblasts, MS-275 treatment inhibited TGF-beta induced phosphorylation of Smad-3, differentiation of renal fibroblasts to myofibroblasts and proliferation of myofibroblasts.
These results demonstrate that class I HDACs are critically involved in renal fibrogenesis and renal fibroblast activation through modulating TGF-beta and EGFR signaling and suggest that blockade of class I HDAC may be a useful treatment for renal fibrosis.
组蛋白去乙酰化酶(HDAC)抑制剂是很有前途的抗纤维化药物;然而,I 类和 II 类 HDAC 的非选择性抑制作用并不能详细阐明肾脏纤维化中单个 HDAC 的功能。在这项研究中,我们研究了选择性 I 类 HDAC 抑制剂 MS-275 在单侧输尿管梗阻(UUO)小鼠模型中对肾脏纤维化发展的影响,以及对培养的肾间质成纤维细胞的激活作用。
方法/发现:通过结扎左输尿管建立 UUO 模型,对侧肾脏作为对照。UUO 损伤后 7 天,肾脏出现纤维化,表现为胶原纤维沉积增加,胶原 I、纤连蛋白和α-平滑肌肌动蛋白(α-SMA)表达增加。MS-275 给药抑制了所有这些纤维化反应,并抑制了 UUO 诱导的转化生长因子-β1(TGF-β)的产生,增加了 TGF-β受体 I 的表达和 Smad-3 的磷酸化。MS-275 还能有效抑制表皮生长因子受体(EGFR)及其下游信号分子信号转导和转录激活因子-3 的磷酸化和表达。此外,I 类 HDAC 抑制作用减少了处于细胞周期 G2/M 期的肾小管细胞数量,这是与 TGF-β1 过度产生相关的细胞事件。在培养的肾间质成纤维细胞中,MS-275 处理抑制了 TGF-β诱导的 Smad-3 磷酸化、肾成纤维细胞向肌成纤维细胞分化和肌成纤维细胞增殖。
这些结果表明,I 类 HDAC 通过调节 TGF-β和 EGFR 信号在肾脏纤维化和肾成纤维细胞激活中起关键作用,并表明阻断 I 类 HDAC 可能是治疗肾脏纤维化的一种有用方法。